JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Effect of shift work on the development of metabolic syndrome after 3 years in Japanese male workers.

A 3-year follow-up study of an occupational cohort was conducted to clarify the effect of the type of shift work on the risk of development of metabolic syndrome (MetS). The subjects were 1,677 Japanese male employees aged 36 to 57. Age, each component of MetS, serum uric acid, serum insulin, lifestyle factors, and occupational position were used for the analyses. The odds ratios (95% confidence intervals) of 2-shift work (n = 686) and 3-shift work (n = 99) against daytime work (n = 868) for the development of MetS, as defined by the National Cholesterol Education Program, were 1.43 (1.05, 1.95) and 0.72 (0.37, 1.41), respectively. When Japanese criteria were adopted for defining MetS, the corresponding odds ratios (95% confidence intervals) were 1.88 (1.29, 2.74) and 0.87 (0.39, 1.97), respectively. The results of the analyses suggested that 2-shift work was a risk factor for the development of metabolic syndrome.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app